Adult Dosing
For using in patients with suboptimal echocardiograms
- 0.5 mL IV prn; if essential administer in increments of 0.5 mL up to 5.0 mL cumulatively in a 10 minute period
- Max dose: 8.7 mL
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
- Serious cardiopulmonary reactions, including fatalities may occur during or following perflutren-containing microsphere administration; patients with pulmonary hypertension or unstable cardiopulmonary conditions including patients receiving mechanical ventilation are at greater risk for these reactions. Monitor vital signs, electrocardiography, and cutaneous oxygen saturation during and for at least 30 minutes after administration of this drug in such patients. On absence of these underlying conditions closely observe patients during and following administration of this drug
- Fatal cardiac or respiratory arrest, loss of consciousness, convulsions, symptomatic arrhythmias, hypotension, respiratory distress or cardiac ischemia have been reported on postmarketing use
- Always keep availability of resuscitation equipment and trained personnel prior to administration of this drug and monitor all patients for acute reactions
- Acute anaphylactoid reactions including shock, bronchospasm, upper airway swelling, loss of consciousness, urticaria and pruritus have been reported on postmarketing surveillance in patients with no prior exposure to perflutren-containing microsphere products. Monitor patients for signs and symptoms of anaphylactoid reactions
- Systemic embolization of human albumin may occur in patients with cardiac shunts. Avoid administration of this drug by intra-arterial injection
- Microsphere cavitation or rupture leading to ventricular arrhythmias may occur as a result of high ultrasound mechanical index values. Additionally, end-systolic triggering with high mechanical indices may cause ventricular arrhythmias
- The safety of this drug at mechanical indices >0.8 and with the use of end-systolic triggering is not established
- Remote theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) exists
- Positive skin test may occur
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
Pregnancy Category:C
Breastfeeding: Unknown whether this drug is excreted in human milk. As many drugs are excreted in human milk manufacturer advises caution.
